Schweizer E, Rickels K
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia 19104-2649, USA.
J Clin Psychiatry. 1997;58 Suppl 11:30-8.
The development of new treatments for generalized anxiety disorder increasingly has been sabotaged by a high placebo-response rate. As a consequence, and in contrast to the surge of approvals for new antidepressants, only one new anxiolytic has been approved by the U.S. Food and Drug Administration in the past 15 years. This article presents a brief review of factors that contribute to the placebo response in treatment studies of generalized anxiety. Since anxiety is a normal emotion that is sensitive to a variety of life stresses, it is particularly difficult to achieve the primary goal of a clinical trial, which is to extract the "signal" of a drug effect from the "noise" of background fluctuations in symptoms. Data from the published literature and from the authors' research unit concerning placebo-response trends are reviewed.
广泛性焦虑症新疗法的研发越来越受到高安慰剂反应率的破坏。因此，与新型抗抑郁药获批数量激增形成对比的是，在过去15年里，美国食品药品监督管理局仅批准了一种新型抗焦虑药。本文简要回顾了在广泛性焦虑症治疗研究中导致安慰剂反应的因素。由于焦虑是一种对各种生活压力敏感的正常情绪，因此特别难以实现临床试验的主要目标，即从症状背景波动的“噪音”中提取药物效应的“信号”。本文回顾了已发表文献和作者研究单位关于安慰剂反应趋势的数据。
